These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31282236)

  • 1. DAHANCA 9 - a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC).
    Evensen JF; Sand Hansen H; Overgaard M; Johansen J; Andersen LJ; Overgaard J
    Acta Oncol; 2019 Oct; 58(10):1502-1505. PubMed ID: 31282236
    [No Abstract]   [Full Text] [Related]  

  • 2. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
    Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
    Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
    [No Abstract]   [Full Text] [Related]  

  • 3. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.
    Lassen P; Eriksen JG; Krogdahl A; Therkildsen MH; Ulhøi BP; Overgaard M; Specht L; Andersen E; Johansen J; Andersen LJ; Grau C; Overgaard J;
    Radiother Oncol; 2011 Jul; 100(1):49-55. PubMed ID: 21429609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
    Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DAHANCA 33: functional image-guided dose-escalated radiotherapy to patients with hypoxic squamous cell carcinoma of the head and neck (NCT02976051).
    Saksø M; Primdahl H; Johansen J; Nowicka-Matus K; Overgaard J;
    Acta Oncol; 2020 Feb; 59(2):208-211. PubMed ID: 31805799
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.
    Dobrowsky W; Naudé J
    Radiother Oncol; 2000 Nov; 57(2):119-24. PubMed ID: 11054514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.
    Bourhis J; Overgaard J; Audry H; Ang KK; Saunders M; Bernier J; Horiot JC; Le Maître A; Pajak TF; Poulsen MG; O'Sullivan B; Dobrowsky W; Hliniak A; Skladowski K; Hay JH; Pinto LH; Fallai C; Fu KK; Sylvester R; Pignon JP;
    Lancet; 2006 Sep; 368(9538):843-54. PubMed ID: 16950362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma.
    Lyhne NM; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Evensen J; Mortensen HR; Overgaard J
    Radiother Oncol; 2015 Oct; 117(1):91-8. PubMed ID: 26255764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
    Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
    J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Mortality after Radical Radiotherapy in Head and Neck Cancer - A Nationwide Analysis from the Danish Head and Neck Cancer Group (DAHANCA) Database.
    Jensen KH; Vogelius I; Kristensen CA; Andersen E; Overgaard J; Eriksen JG; Primdahl H; Johansen J; Farhadi M; Andersen M; Friborg J
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):57-63. PubMed ID: 32698963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer.
    Mortensen HR; Overgaard J; Specht L; Overgaard M; Johansen J; Evensen JF; Andersen LJ; Andersen E; Grau C
    Radiother Oncol; 2012 Apr; 103(1):69-75. PubMed ID: 22398313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic use of patient reported outcome during radiotherapy for head and neck cancer: study protocol for the national DAHANCA 38 trial.
    Holländer-Mieritz C; Johansen J; Taarnhøj GA; Johansen C; Vogelius IR; Kristensen CA; Pappot H
    Acta Oncol; 2020 May; 59(5):603-607. PubMed ID: 32056473
    [No Abstract]   [Full Text] [Related]  

  • 15. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    Staar S; Rudat V; Stuetzer H; Dietz A; Volling P; Schroeder M; Flentje M; Eckel HE; Mueller RP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1161-71. PubMed ID: 11483325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcome of elderly patients (≥ 78 years) with head and neck squamous cell carcinoma: A single center experience.
    Liu Y; Wang D; Deng Y; Zhang S
    Biomol Biomed; 2024 Sep; 24(5):1417-1423. PubMed ID: 38733633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boron neutron capture therapy: moving towards targeted therapy for locally recurrent head and neck squamous cell carcinoma.
    Sun Y
    Mil Med Res; 2019 Oct; 6(1):32. PubMed ID: 31651361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early (90-day) mortality after radical radiotherapy for head and neck squamous cell carcinoma: A population-based analysis.
    Hamilton SN; Tran E; Berthelet E; Wu J; Olson R
    Head Neck; 2018 Nov; 40(11):2432-2440. PubMed ID: 30295975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer.
    Dobrowsky W; Naudé J; Widder J; Dobrowsky E; Millesi W; Pavelka R; Grasl C; Reichel M
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):803-6. PubMed ID: 9845100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.